Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Merck is also developing a subcutaneous formulation of Keytruda ... On the other hand, AbbVie has faced its biggest challenge — Humira’s patent cliff — quite well and looks well-positioned ...

The global high potency API contract manufacturing market, valued at USD 8 billion in 2022, is poised for robust growth, with projections to reach USD 16 billion by 2032. This remarkable expansion, ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

The subcutaneous version still needs to be administered ... with natalizumab and a high-concentration formulation of AbbVie's immunology drug Humira (adalimumab) highlighted as those with the ...

Tepkinly is given in hospital as a once-weekly subcutaneous injection for 12 weeks ... competition to its immunology blockbuster Humira (adalimumab).

Merck’s application for subcutaneous Keytruda is still under review ... as physicians and health systems struggle to adapt to the new treatment paradigm. Both Humira and Stelara work by tamping down ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Overall, subcutaneous abatacept demonstrated similar clinical efficacy ... design because of an inability to mask commercially acquired Humira; it was also impractical to require weekly visits for ...